Published in FASEB J on January 15, 2008
G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov (2011) 3.31
SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A (2008) 1.58
Orexin/hypocretin receptor signalling: a functional perspective. Br J Pharmacol (2014) 0.92
Orexin/hypocretin receptor signalling cascades. Br J Pharmacol (2014) 0.92
The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs. Br J Pharmacol (2012) 0.89
Dynein light chain Tctex-type 1 modulates orexin signaling through its interaction with orexin 1 receptor. PLoS One (2011) 0.80
Comparative analysis of nonaspanin protein sequences and expression studies in zebrafish. Immunogenetics (2010) 0.79
Orexin-1 receptor co-localizes with pancreatic hormones in islet cells and modulates the outcome of streptozotocin-induced diabetes mellitus. PLoS One (2010) 0.78
The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor contains an immunoreceptor tyrosine-based inhibitory motif that activates Shp2. J Virol (2010) 0.78
OX1 orexin/hypocretin receptor activation of phospholipase D. Br J Pharmacol (2012) 0.77
Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis. Br J Pharmacol (2015) 0.76
Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice. PLoS One (2017) 0.75
Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem (2002) 2.14
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol (2012) 1.64
Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One (2010) 1.54
Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem (2004) 1.53
Class-B GPCR activation: is ligand helix-capping the key? Trends Biochem Sci (2008) 1.29
Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol (2003) 1.21
Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Mol Cancer Res (2004) 1.10
Orexins acting at native OX(1) receptor in colon cancer and neuroblastoma cells or at recombinant OX(1) receptor suppress cell growth by inducing apoptosis. J Biol Chem (2004) 1.02
VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol (2012) 0.99
Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling. J Biol Chem (2006) 0.99
Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor. J Med Chem (2009) 0.99
Identification of cytoplasmic domains of hVPAC1 receptor required for activation of adenylyl cyclase. Crucial role of two charged amino acids strictly conserved in class II G protein-coupled receptors. J Biol Chem (2003) 0.95
The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. Mol Endocrinol (2007) 0.95
Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase. Int J Cancer (2009) 0.92
Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction. FASEB J (2012) 0.91
Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides (2008) 0.91
The family B1 GPCR: structural aspects and interaction with accessory proteins. Curr Drug Targets (2012) 0.90
Orexin-induced apoptosis: the key role of the seven-transmembrane domain orexin type 2 receptor. Endocrinology (2006) 0.90
Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor. Regul Pept (2004) 0.89
Orexins control intestinal glucose transport by distinct neuronal, endocrine, and direct epithelial pathways. Diabetes (2007) 0.88
Trypsin is produced by and activates protease-activated receptor-2 in human cancer colon cells: evidence for new autocrine loop. Life Sci (2002) 0.88
Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis. FASEB J (2009) 0.88
Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis. Cancer Res (2011) 0.87
Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor. Mol Pharmacol (2003) 0.84
Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor. J Biol Chem (2003) 0.83
The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor. J Mol Neurosci (2008) 0.83
Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP. J Biol Chem (2004) 0.82
VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling. J Clin Invest (2011) 0.81
Human VPAC1 receptor selectivity filter. Identification of a critical domain for restricting secretin binding. J Biol Chem (2002) 0.80
Biological and structural analysis of truncated analogs of PACAP27. J Mol Neurosci (2008) 0.78
PAR-2 activation increases human intestinal mucin secretion through EGFR transactivation. Biochem Biophys Res Commun (2007) 0.78
PACAP prevents toxicity induced by cisplatin in rat and primate neurons but not in proliferating ovary cells: involvement of the mitochondrial apoptotic pathway. Neurobiol Dis (2008) 0.78
The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling. Ann N Y Acad Sci (2006) 0.77
Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge. Peptides (2007) 0.77
Production and purification of large quantities of the functional N-terminal ectodomain of human VPAC1 receptor. J Mol Neurosci (2008) 0.76
Kallikrein-related peptidase signaling in colon carcinoma cells: targeting proteinase-activated receptors. Biol Chem (2012) 0.75
Expression and GTP sensitivity of peptide histidine isoleucine high-affinity-binding sites in rat. Ann N Y Acad Sci (2006) 0.75
Strategies for studying the ligand binding site of GPCRs: photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs. Methods Enzymol (2013) 0.75
Characterization of the new photoaffinity probe (Bz2-K24)-VIP. Ann N Y Acad Sci (2006) 0.75
[How to turn a silent proapoptotic gene in a potent antitumoral target in colorectal cancer]. Med Sci (Paris) (2012) 0.75
[MicroRNAs and intestinal pathophysiology]. Med Sci (Paris) (2007) 0.75